Scientists Must Learn to Lobby

Mention lobbying to a scientist and until quite recently the typical response was disinterest or discomfort. Active involvement in the political fray over the public funding of research has simply not been within the experience of most scientists. Moreover, the pejorative connotations evoked by terms like "lobby" and "political action committee" only reinforce an innate distaste many hold for overt forms of influencing decision-makers in government. That distaste has been enormously strengthened

Written byEugene Garfield
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Historically, scientists have been more comfortable with indirect—or so-called non-lobbying—lobbying efforts, such as those of the academies and national associations. But that is changing, here and abroad.

"The dependence of scientific research on the large sums that have to be voted on by popularly elected governments and legislative bodies has focused the minds of scientists on the public arena to an extent that is unprecedented," Edward Shils, professor of sociology at the University of Chicago, observed recently. "The freedom they enjoyed when research projects were small and demands for practical results were less insistent is no longer the natural and inevitable condition of scientific research. The outer world has forced itself into the horizon of scientists as never before." ("Science and Scientists in the Public Arena," American Scholar, Spring 1987, p. 195) Indeed, necessity has converted many of us to political involvement. Here are a few examples from around the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies